Stone House Investment Management LLC Has $60,000 Position in Amgen Inc. (NASDAQ:AMGN)

Stone House Investment Management LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 553.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209 shares of the medical research company’s stock after acquiring an additional 177 shares during the quarter. Stone House Investment Management LLC’s holdings in Amgen were worth $60,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of AMGN. Oakworth Capital Inc. boosted its holdings in Amgen by 101.5% in the fourth quarter. Oakworth Capital Inc. now owns 1,445 shares of the medical research company’s stock valued at $416,000 after acquiring an additional 728 shares during the last quarter. Guidance Capital Inc. boosted its holdings in Amgen by 14.2% during the fourth quarter. Guidance Capital Inc. now owns 5,139 shares of the medical research company’s stock worth $1,528,000 after buying an additional 638 shares during the last quarter. TRUE Private Wealth Advisors boosted its holdings in Amgen by 38.5% during the fourth quarter. TRUE Private Wealth Advisors now owns 2,567 shares of the medical research company’s stock worth $739,000 after buying an additional 714 shares during the last quarter. Scissortail Wealth Management LLC bought a new position in Amgen during the fourth quarter worth about $1,009,000. Finally, Tyche Wealth Partners LLC bought a new position in Amgen during the fourth quarter worth about $1,467,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on AMGN shares. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Oppenheimer reiterated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. BMO Capital Markets raised Amgen from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Finally, Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and lifted their target price for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.38.

Amgen Stock Performance

NASDAQ AMGN traded down $0.58 on Wednesday, reaching $265.06. The stock had a trading volume of 1,396,120 shares, compared to its average volume of 2,850,758. The company has a market cap of $142.05 billion, a P/E ratio of 21.25, a price-to-earnings-growth ratio of 2.47 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a fifty day moving average of $278.62 and a two-hundred day moving average of $281.49.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.09 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.47 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.40%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.